Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.Frontiers in Oncology|March 30, 2022
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary FunctionShlomit Jessel, Sarah A Weiss, Matthew Austin, et al.JCI Insight|November 19, 2024
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinomaDavid A Schoenfeld, Dijana Djureinovic, David G Su, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint InhibitorsAnita Gul, Tyler F Stewart, Charlene M Mantia, et al.Journal for Immunotherapy of Cancer|August 16, 2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesDavid A Schoenfeld, Myrto Moutafi, Sandra Martinez, et al.Journal for Immunotherapy of Cancer|April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.Journal for Immunotherapy of Cancer|September 11, 2025
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetesLilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, et al.Cancer|November 15, 2024
Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumorsPhilippos Apolinario Costa, Arshia Arora, Yannelys Fernandez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1Sarah A Weiss, Dijana Djureinovic, Shlomit Jessel, et al.Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.Pageof 3